

# NEWPORT VISION PREMIUM™

POWERFUL INTEGRATED API INTELLIGENCE WITH UNIQUE ANALYSIS



## HOW YOU BENEFIT

- Monthly intelligence updates
- Easy-to-use web-based interface
- Comprehensive training and technical support
- Integrated on-line help
- Zero cost deployment
- Secure, confidential hosted access

## WHERE YOU CAN USE IT

- Company intelligence
- Business development and licensing
- Brand and lifecycle management
- Legal and intellectual property
- Product intelligence

## SPOT THE DEVELOPING GENERIC COMPETITION. FIND THE OPPORTUNITY

Newport Vision Premium™ is the most advanced competitive intelligence, business development and global active pharmaceutical ingredient (API) sourcing system from Thomson Reuters, the industry authority on the global generics market.

Created specifically for demanding professionals in innovator, specialty and niche-brand pharmaceutical companies, it ensures you don't miss the developing generic competition that can impact your sales, or the licensing opportunity that can build on your strengths.

Its proven analytics can warn of potential generic activity four to seven years ahead of loss of exclusivity.

Newport Vision Premium offers the same unique data and features as the respected, industry-standard Newport Vision CI™ system, with the addition of current- and previous-year kilogram and International Units active ingredient consumption data by region by dose form, and routes of synthesis data for more than 2,500 APIs.

With its sophisticated targeting capabilities, Newport Vision Premium can help you to identify, profile and evaluate licensing, acquisition and partnership opportunities in launched and approved products worldwide.

You can discover the niche opportunities that match your strategic needs and unique strengths in research, sales or marketing.

## COMPETITIVE INTELLIGENCE

- Identify the likely source, timing and impact of generic competition on your branded products
- Detect and interpret the earliest signs of alternative form and polymorph development and API manufacture
- Quickly assess competitive dynamics for individual products, groups of products, or across therapy areas
- Assess likely generic competitors and API suppliers by analyzing worldwide API consumption
- Evaluate strategies based on available routes of synthesis and kilogram API consumption data and trends

See worldwide sales together with API consumption data and trends at a glance

Quickly locate Paragraph IV patent challenge information.

See who is producing the API – find alternative and possibly less expensive suppliers.



**BUSINESS DEVELOPMENT AND LICENSING**

- Identify and evaluate global niche brands and candidate products for acquisition or licensing
- Profile worldwide business partners for alliances, supply, out-licensing and manufacture
- Discover generic products and opportunities first
- Identify likely primary or backup suppliers of APIs

**BRAND AND LIFECYCLE MANAGEMENT**

- Determine if there are likely to be no generics, saving costly and perhaps needless line extension programs
- Identify reliable, lower-cost, alternative or exclusive API sources for existing products
- Improve planning of development pipelines
- Adjust sales and revenue forecasting based on the timing and extent of future generic competition

**LEGAL AND INTELLECTUAL PROPERTY**

- Spot potential patent challenges early
- Formulate IP protection strategies at the earliest opportunity
- Gather all the facts, before you hire costly specialist investigative firms and outside counsel

**PRODUCT INTELLIGENCE**

- Sales, launch, approval and regulatory data for more than 40,000 launched products containing over 10,000 different active ingredients
- Unique, early API manufacturing intelligence, the earliest and most reliable indicator of potential generic competition
- Worldwide patent families and individual patents for more than 90 countries
- Comprehensive Supplementary Protection Certificate (SPC) data for Europe<sup>1</sup>
- Projected loss of exclusivity dates for US, European and Japanese markets
- Sales figures by molecule and by dosage form for major world market regions, including two-year sales history<sup>2</sup>
- Current retail and hospital dose pack pricing for each dose form and strength of all products in more than 65 countries<sup>2</sup>

- Paragraph IV patent challenges commentaries, including company identities, FTF and status of litigation for more than 190 products
- Product launch<sup>2</sup> and first market authorization data, country-by-country
- Orange Book approved dose forms, US Drug Master Files, EU Certificates of Suitability, FDA warning letters and issues, and Japanese DMFs and DEA registrations
- Labeling and prescribing data for more than 1,800 unique products
- Chemical structure diagram and details of alternative structures for thousands of products
- Routes of synthesis, including intermediates and reagents with patent and literature references for thousands of products<sup>3</sup>
- Powerful indexing and searching of products according to FDA approved indication and technology class
- Ability to target products utilizing over 40 different search criteria
- API consumption by dose form by region for the current and previous year<sup>2</sup>

**COMPANY INTELLIGENCE**

- Profiles of more than 20,000 companies and corporate groups, including subsidiary, launch, approvals, regulatory filings and APIs manufactured
- Detailed manufacturing capabilities for an increasing number of sites
- Alerting on key changes in products and companies, including new regulatory filings and approvals
- Reports on key conferences affecting the generics industry

<sup>1</sup> Source: Cabinet Alice de Pastors

<sup>2</sup> Source: IMS Health, copyright 2008, all rights reserved

<sup>3</sup> Source: Prous Science, a Thomson Reuters business

Route ID	Route Name	Starting Material	Intermediates	Reagents	Literature References
1	...	...	...	...	...
2	...	...	...	...	...
3	...	...	...	...	...

Examine routes of synthesis together with intermediates, reagents, and patent and literature references.

**Scientific Head Offices****Americas**

Philadelphia +1 800 336 4474  
+1 215 386 0100

**Europe, Middle East and Africa**

London +44 20 7433 4000

**Asia Pacific**

Singapore +65 6411 6888  
Tokyo +81 3 5218 6500

For a complete office list visit:

[scientific.thomsonreuters.com/contact](http://scientific.thomsonreuters.com/contact)

**GET A QUOTATION**

Contact us today to request a no obligation quotation or visit [scientific.thomsonreuters.com](http://scientific.thomsonreuters.com)

